Navigation Links
Lilly Announces Continued Commitment to Transparency with Faculty Registry
Date:7/31/2009

INDIANAPOLIS, July 31 /PRNewswire-FirstCall/ -- Today Eli Lilly and Company (NYSE: LLY) launched an online registry detailing recent payments it has made to physicians and other health care professionals - a report known as its "faculty registry." The data are for the first quarter of 2009; Lilly will update the registry quarterly going forward.

Lilly faculty are physicians and other health care professionals contracted to provide specific services on behalf of Lilly and the Lilly alliance partnerships. Faculty appearing in the registry either advised Lilly or conducted medical lectures designed for health care professionals and patient education. The site discloses each professional's name, location, description of the services provided and the compensation paid, among other details.

"This registry is consistent with Lilly's efforts to increase transparency," said Jack Harris, M.D., Lilly's vice president of its U.S. medical division. "We see greater transparency as integral to rebuilding trust in our industry."

Nearly 3,400 physicians and other health care professionals are in the dataset. The average payment per service provided is just over $1,000, with health care professionals conducting six activities on average. The data are available at www.lillyfacultyregistry.com.

"Our contracted faculty are key resources in our efforts to improve individual patient outcomes," Harris said. "They advise us on how to bring the best new cures and treatments to market, and give lectures to their peers on Lilly products and disease-state information to help keep them current on the ever-changing field of medicine. And many of our faculty educate patients, at the request of their treating physician, on how to use the Lilly medicine prescribed to them."

Lilly's faculty registry is part of its commitment to enhancing transparency. In 2004, Lilly became the first company to voluntarily make public its clinical trials and its clinical trials data at www.lillytrials.com. In 2007, Lilly added another first by publicly reporting all of its educational grants and charitable contributions and, each quarter, posting the data online at www.lillygrantoffice.com.

Lilly announced last September it would begin to voluntarily disclose physician payments starting in the second half of 2009. In February 2009, Lilly entered into a Corporate Integrity Agreement with the Office of the Inspector General of the U.S. Department of Health and Human Services and was required to disclose the information.

About Lilly

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers - through medicines and information - for some of the world's most urgent medical needs. Additional information about Lilly is available at www.lilly.com.

(Logo: http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO)

C-LLY


'/>"/>
SOURCE Eli Lilly and Company
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Lilly to Unveil More Than 30 Studies at Premier Lung Cancer Meeting
2. Lilly Receives Award From National Medical Association
3. FDA Approves Expanded Use of Lillys FORTEO(R) [teriparatide (rDNA origin) injection] to Treat Glucocorticoid-Induced Osteoporosis
4. Lilly Reports Solid Second-Quarter 2009 Results, Raises EPS Guidance
5. Daiichi Sankyo and Lilly Receive U.S. FDA Approval for Effient(TM)
6. Lilly Celebrates Its 35th Year as a Supporter of the Indiana Black Expo
7. Lilly Sets Date and Conference Call for Second-Quarter 2009 Financial Results Announcement
8. Lilly Receives Fourth FDA Approval for ALIMTA(R) (pemetrexed for injection)
9. Lilly Declares Third-Quarter Dividend
10. New Therapies, Including Novel Biologic Agents from Elan/Wyeth and Eli Lilly, Will Drive Robust 11 Percent Annual Growth In the Alzheimers Disease Market
11. Eli Lilly and Company Announces New Drug Discovery Initiative
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/10/2016)... ... December 10, 2016 , ... The ... PATS recently joined forces with other healthcare organizations to promote diabetes education at ... in Harrisburg, featured a variety of speakers from around the Commonwealth of Pennsylvania. ...
(Date:12/9/2016)... , ... December 09, 2016 , ... ... and aural rehabilitation—provided by audiologists—to remain a critical part of public access to ... Drug Administration (FDA) announced this week that, starting immediately, it would ...
(Date:12/9/2016)... (PRWEB) , ... December 09, 2016 , ... ... miniature, folded, pharmaceutical inserts and outserts. As a means of expanding capabilities ... addition will enable Flottman to individually code professional inserts (PIs) and patient package ...
(Date:12/9/2016)... ... December 09, 2016 , ... ... its 10th anniversary with the grand opening of the Sober College Robert Pfeifer ... spanned two days, December 2-3, and was attended by an overwhelming amount of ...
(Date:12/9/2016)... (PRWEB) , ... December 09, 2016 , ... ... Ball at The Pierre Hotel in New York, NY, on December 3rd, to ... dignitaries and physicians attended the annual event, which raised over $1 million - ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)...  Eli Lilly and Company (NYSE: LLY ... EXPEDITION3 trial at the 9 th Clinical Trials ... did not meet the primary endpoint in the EXPEDITION3 ... with mild dementia due to Alzheimer,s disease (AD), and ... the treatment of mild dementia due to AD. ...
(Date:12/8/2016)... QUEBEC CITY , Dec. 8, 2016 /PRNewswire/ ... key US patents for improving the accuracy, reproducibility ... CD images in long and small bone orthopaedic ... proprietary approach to creating personalized orthopaedic restorations based ... create personalized orthopaedic restorations, the company harnesses the ...
(Date:12/8/2016)... , Dec. 8, 2016  EIP Pharma, ... has obtained proof-of-mechanism for neflamapimod (previously code named ... Phase 2a clinical trials that demonstrated significant Alzheimer,s ... 302 (12-week treatment) and Study 303 (6-week treatment) ... Trials in Alzheimer,s Disease (CTAD) scientific conference in ...
Breaking Medicine Technology: